Investment Thesis
Roivant Sciences faces severe operational distress with collapsing revenue (-71.6% YoY) and unsustainable cash burn of $750M annually against only $8.3M revenue. Despite a strong balance sheet providing temporary runway, the company's massive operating losses and negative profitability across all metrics indicate fundamental business model failure requiring immediate strategic restructuring or asset liquidation.
Strengths
- Strong balance sheet with $5.7B total assets and $4.5B stockholders equity provides short-term financial cushion
- Adequate liquidity with $1.4B cash reserves and exceptional current ratio of 18.37x eliminates immediate solvency risk
- Minimal financial leverage at 0.07x debt-to-equity ratio reduces leverage risk despite operational challenges
Risks
- Severe revenue collapse of 71.6% YoY to $8.3M indicates fundamental business deterioration or major product/partnership failure
- Unsustainable cash burn of $750M annually against $1.4B reserves provides less than 2 years of operational runway without revenue inflection
- Massive operating losses of $515M on minimal revenue demonstrates inability to support current cost structure; operating margin of -6235.7% is untenable
Key Metrics to Watch
- Quarterly revenue trend stabilization and growth trajectory
- Operating cash burn rate reduction and path to cash flow breakeven
- Clinical pipeline progress and regulatory approval milestones
Financial Metrics
Revenue
8.3M
Net Income
-299.8M
EPS (Diluted)
$-0.54
Free Cash Flow
-758.6M
Total Assets
5.7B
Cash
1.4B
Profitability Ratios
Gross Margin
N/A
Operating Margin
-6,235.7%
Net Margin
-3,629.2%
ROE
-6.6%
ROA
-5.3%
FCF Margin
-9,183.5%
Balance Sheet & Liquidity
Current Ratio
18.37x
Quick Ratio
18.25x
Debt/Equity
0.07x
Debt/Assets
7.3%
Interest Coverage
-38.44x
Long-term Debt
311.7M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-22T07:42:19.940756 |
Data as of: 2026-03-31 |
Powered by Claude AI